C1-Esterase Inhibitor
Brand names: Haegarda · Active ingredient: Human C1-Esterase Inhibitor
In short: HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.
What is C1-Esterase Inhibitor used for?
HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.
C1-Esterase Inhibitor dosage
After reconstitution, for subcutaneous use only.
HAEGARDA is intended for self (or caregiver)-administration after reconstitution at a dose of 60 International Units (IU) per kg body weight by subcutaneous (S.C.) injection twice weekly (every 3 or 4 days). The patient or caregiver should be trained on how to administer HAEGARDA.
HAEGARDA is provided as a freeze-dried powder for reconstitution with Sterile Water for Injection, USP.
Check the expiration date on the product vial label. Do not use beyond the expiration date.
Work on a clean surface and wash hands before performing the following procedures.
Prepare and administer using aseptic techniques .
Use a silicone-free syringe for reconstitution and administration.
Each vial of HAEGARDA is for single-dose only. Promptly use the reconstituted solution. The solution must be used within 8 hours. Discard partially used vials. HAEGARDA contains no preservative.
Do not freeze the reconstituted solution.
Use either the Mix2Vial® transfer set provided with HAEGARDA or a commercially available double-ended needle and vented filter spike .
Reconstitution
The procedures below are provided as general guidelines for the reconstitution and administration of HAEGARDA.
HAEGARDA Reconstitution Instructions
1.Ensure that the HAEGARDA vial and Sterile Water for Injection (diluent) vial are at room temperature.
2.Place the HAEGARDA vial, diluent vial and Mix2Vial transfer set on a flat surface.
3.Remove flip caps from the HAEGARDA and diluent vials.
4.Wipe the stoppers with an alcohol swab and allow to dry prior to opening the Mix2Vial transfer set package.
5.Open the Mix2Vial transfer set package by peeling away the lid (Figure 1). Do not remove the device from the package.
Figure 1
6.Place the diluent vial on a flat surface and hold the vial tightly. Grip the Mix2Vial transfer set together with the clear package and push the plastic spike at the blue end of the Mix2Vial transfer set firmly through the center of the stopper of the diluent vial (Figure 2).
Figure 2
7.Carefully remove the clear package from the Mix2Vial transfer set. Do not remove the Mix2Vial transfer set or touch the exposed end of the device (Figure 3).
Figure 3
8.With the HAEGARDA vial placed firmly on a flat surface, invert the diluent vial with the Mix2Vial transfer set attached and push the plastic spike of the transparent adapter firmly through the center of the stopper of the HAEGARDA vial (Figure 4). The diluent will automatically transfer into the HAEGARDA vial.
Figure 4
9.With the diluent and HAEGARDA vial still attached to the Mix2Vial transfer set, gently swirl the HAEGARDA vial to ensure that the powder is fully dissolved (Figure 5). Do not shake the vial. …
How to take C1-Esterase Inhibitor — instructions & advice from the label
See FDA-approved patient labeling (Patient Product Information).
All risks and benefits of HAEGARDA should be discussed with the patient/caregiver before prescribing or administering it to the patient.
Inform patients/caregivers to immediately report the following to their physician:
Signs and symptoms of allergic hypersensitivity reactions, such as hives, tightness of the chest, difficulty breathing, wheezing, hypotension and/or anaphylaxis experienced during or after injection of HAEGARDA .
Signs and symptoms of a thromboembolic event, including pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness or weakness on one side of the body .
Inform all patients/caregivers:
HAEGARDA is indicated for HAE prophylaxis and should not be used for the treatment of acute HAE attacks. Patients/caregivers should be counselled regarding the appropriate course of action if breakthrough HAE attacks occur while on HAEGARDA, including:
Individualized rescue treatment for acute HAE attacks. …
Warnings & precautions
Do not take this medicine if: HAEGARDA is contraindicated in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or its excipients .
The physician should discuss the risks and benefits of this product with the patient before prescribing or administering it to the patient .
Initiate individualized treatment in case of an acute HAE attack.
Severe hypersensitivity reactions may occur. The signs and symptoms of hypersensitivity reactions may include hives (local and generalized), tightness of the chest, difficulty breathing, wheezing, hypotension, and/or anaphylaxis during or after injection of HAEGARDA. In case of severe hypersensitivity, discontinue HAEGARDA administration and institute appropriate treatment. Epinephrine should be immediately available for treatment of severe hypersensitivity reaction .
At the recommended subcutaneous dose, a causal relationship between thromboembolic events (TEEs) and the use of HAEGARDA has not been established . Thrombosis has occurred in treatment attempts with high doses of C1-INH intravenous (I.V.) for prevention or therapy of capillary leak syndrome before, during or after cardiac surgery (unapproved indication and dose).
Because HAEGARDA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by processes demonstrated to inactivate and/or remove certain viruses during manufacturing . …
C1-Esterase Inhibitor side effects
Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Of the 90 subjects randomized in the double-blind, placebo-controlled, cross-over study (Study 1) , 86 subjects received at least one dose of HAEGARDA and 86 subjects received at least one dose of placebo (Table 1). A total of 5081 injections of HAEGARDA and placebo were administered over a range of 3 to 19 weeks (median of 16.6 weeks for HAEGARDA; median of 16.3 weeks for placebo). Eligible patients were also able to participate in a randomized, open-label, active treatment-controlled study (Study 2) for up to 140 weeks (n=120).
MedDRA System Organ Class | Adverse Reaction | HAEGARDA | Placebo (N=86)
60 IU/kg(N=43) | 40 IU/kg(N=43) | OverallIncludes subjects who were treated with 40 IU/kg or 60 IU/kg HAEGARDA.
(N=86)
n (%) | n (%) | n (%) | n (%)
N = number of subjects receiving the treatment; n = number of subjects experiencing ≥1 event. …
Drug interactions
No interaction studies have been conducted.
About this medicine
HAEGARDA is a human plasma-derived, purified, pasteurized, lyophilized concentrate of C1-INH to be reconstituted for S.C. administration. HAEGARDA is prepared from large pools of human plasma from U.S. donors. The potency of C1-INH is expressed in International Units (IU), which is related to the current WHO Standard for C1-INH products.
Reconstituted HAEGARDA has a concentration of 500 IU/mL C1-INH, 65 mg/mL total protein, 10 mg/mL glycine, 8.5 mg/mL sodium chloride and 2.7 mg/mL sodium citrate.
C1 Esterase Inhibitor
C1-INH is a soluble, single-chain highly glycosylated protein containing 478 amino acid residues which belongs to the serine protease inhibitor (serpin) family.
All plasma used in the manufacturing of C1-INH is obtained from U.S. donors and is tested using serological assays for hepatitis B surface antigen and antibodies to HIV-1/2 and HCV. Additionally, the plasma is tested with Nucleic Acid Testing (NAT) for HBV, HCV, HIV-1 and HAV and found to be non-reactive (negative). The plasma is also tested by NAT for Human Parvovirus B19. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e270ad38-adc4-4ed5-88e3-943b93d20a57. Read the full official label on DailyMed.